Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

HTLV-1 study tracks survival to unlock secrets of rare Virus-Linked cancer

NCT ID NCT05237245

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 69 people infected with HTLV-1, some of whom have developed a rare blood cancer called adult T-cell leukemia/lymphoma. Researchers will track survival rates over 2 and 5 years, along with viral levels and genetic markers. The goal is to better understand how the virus causes disease and how patients fare over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could provide a clearer picture of how HTLV-1 affects the body over time, helping doctors predict outcomes and plan better care.
What could go wrong
This is an observational study, not a treatment trial. It will not test any new drug or therapy, so it cannot directly lead to a cure or new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 69 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2022

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with lymphoproliferation induced by HTLV-1 (or HTLV-1 adult T-cell lymphoma / leukemia) and HTLV-1 infected patients

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years old or older * HTLV-1 infected * T lymphoproliferation induced by HTLV-1 (cohort 1) * without T lymphoproliferation induced by HTLV-1 (cohort 2) * informed and accepted the collection of data Exclusion Criteria \- Patients refusal of participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HTLV-1 adult T-cell lymphoma / leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adult T-cell leukemia/lymphoma human T-lymphotropic virus 1 infectious disease leukemia lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HTLV-1 adult T-cell lymphoma / leukemia HTLV-1 infection Lymphoproliferation induced by HTLV-1

Contacts and locations

Locations

  • Hôpital Necker Enfants Malades

    Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.